NCT04305795View on ClinicalTrials.gov

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell CarcinomaLocally Advanced Cutaneous Squamous Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma
Interventions
BIOLOGICAL

200 mg Pembrolizumab

every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.

BIOLOGICAL

350 mg Cemiplimab

every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.

COMBINATION_PRODUCT

ASP-1929 PIT

"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."

Trial Locations (7)

19107

Thomas Jefferson University, Philadelphia

33136

University of Miami Hospital and Clinics, Miami

37203

Vanderbilt-Ingram Cancer Center, Nashville

40536

University of Kentucky, Lexington

55905

Mayo Clinic, Rochester

77030

University of Texas, MD Anderson Cancer Center, Houston

97213

Providence Medical Center, Portland

All Listed Sponsors
lead

Rakuten Medical, Inc.

INDUSTRY